Search results for abx831380

Lanadelumab, Abbexa, abx831380

Lanadelumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KLKB1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials. Lanadelumab was developed by Shire and FDA approved on August 28, 2018. 5.